05/04/2026 12:00
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed...

05/04/2026 12:22
Rasan Sustains Growth Trajectory in Q1 2026, Delivering Highest Ever Quarterly Revenue of SAR 261 Million, More Than Doubling Year-on-Year

Rasan Information Technology Company (Tadawul: 8313), the leading Insurtech and Fintech platform in the Kingdom of Saudi Arabia, today announced its financial results for the first quarter of 2026, delivering highest ever quarterly revenue, accelerated profitability, and broad-based growth across all products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504153362/en/Rasan Builds on Momentum Highest-Ever Quarterly Revenue in Q1...

05/04/2026 12:30
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clini...

05/11/2026 13:00
Only 7% of Companies Achieve Full Compliance as Global Expansion Increases Legal Complexity

As businesses accelerate their global expansion in 2026, compliance fails to keep pace. In fact, only 7% of organizations report full compliance across their global entities, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC surveyed 350 general counsel (GCs) and senior legal professionals across Europe, North America, and Asia Pacific to examine how their teams navigate international expansion, regulatory pressure, and the i...

05/04/2026 13:00
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+

Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and art...

05/04/2026 13:00
Airship Announces 2026 Elevate Customer Experience Award Winners

Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, ...

04/24/2026 10:50
SLB Announces First-Quarter 2026 Results

SLB (NYSE: SLB) today announced results for the first-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422463846/en/The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Mar. 31, 2026   Dec. 31, 2025   Mar. 31, 2025   Sequential   Year-on-year Revenue ...